EUVIMEDOpdag EUVIMED
BeobachtungsstudieMultizentrische StudieOpen access · CC BY-NC-ND 4.0

German Cohort Observational Study to Investigate the Short‐ and Long‐Term Safety and Clinical Effectiveness of Afamelanotide 16 mg ( SCENESSE ) in Patients With Erythropoietic Protoporphyria ( EPP )

Bernhard Homey, Kathrin Schelonke, Carla Marie Schlegel, Daniela Bruch-Gerharz, Karsten Weller, Lea Kiefer, Ulrich Stölzel, Petra Staubach-Renz, Joanna Wegner, Regine Keller-Melchior, Gillian Walker, Malgorzata Bochno and 1 more

Photodermatology, Photoimmunology & Photomedicine · 2025

DOI: 10.1111/phpp.13012 ↗

At a glance

Beobachtungsstudie in Photodermatology, Photoimmunology & Photomedicine, 2025. Written by Bernhard Homey and 12 co-authors. Institution: Dept. of Dermatology, Medical Faculty, Porphyria Specialist Center, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany. Major MEDLINE topics: Protoporphyria, Erythropoietic, alpha-MSH, Registries. Cited 2 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: CLINUVEL (UK) LTD.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Afamelanotide 16 mg (SCENESSE) is the first approved treatment for erythropoietic protoporphyria (EPP). EPP is a rare autosomal recessive inherited disorder of the haem biosynthesis pathway, where patients experience severe and debilitating acute phototoxicity. It affects at least one in 140,000 of the European population. A postauthorisation safety study (PASS) and a disease registry were imposed as conditions of the European marketing authorisation.

Objectives

Evaluate the short‐ and long‐term safety and clinical effectiveness of afamelanotide 16 mg in EPP patients enrolled in the PASS in Germany.

Methods

The PASS (EUPAS13004) is an ongoing observational study collecting safety and effectiveness variables from treated and untreated EPP patients in the European EPP Disease Registry. Patients ( n = 200, none untreated) received afamelanotide according to the summary of product characteristics. Treatment‐emergent adverse events were collected as safety variables. Clinical effectiveness was assessed with the EPP‐QoL tool and through treatment continuity.

Results

The short‐ and long‐term safety and benefit–risk profile of afamelanotide under real‐world conditions is consistent with the positive safety profile seen in clinical trials. EPP patients reported a significant increase in QoL compared with baseline values ( p < 0.0001) and 91.0% of patients who started treatment continue being treated. The safety profile of afamelanotide in patients over 70 years of age is consistent with the overall patient population.

Conclusions

Afamelanotide treatment was highly effective and associated with a higher QoL in EPP patients. The study shows a positive safety profile of afamelanotide, with the treatment providing an ongoing clinical benefit.

Subjects

MeSH terms (MEDLINE)

Protoporphyria, Erythropoieticalpha-MSHRegistriesHumansFemaleMaleGermanyAdultAdolescentChildMiddle AgedChild, PreschoolQuality of Life

Author keywords

SCENESSEafamelanotideerythropoietic protoporphyriaphotoprotectionporphyriareal‐world evidence

Substances

afamelanotidealpha-MSH

Authors and institutions

  • Dept. of Dermatology, Medical Faculty, Porphyria Specialist Center, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
  • Institute for Allergology, Charite, Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin und Humboldt Universität zu Berlin, Berlin, Germany; FrauenhoferInstitute for Translational Medicine and Phar…
  • Clinic for Internal Medicine II, Porphyria Specialist Center, Chemnitz, Germany.
  • University Medical Center of Johannes Gutenberg University, Mainz, Germany.
  • Clinuvel (UK) Ltd, Leatherhead, UK.

Funding

  • CLINUVEL (UK) LTD

Cite

APA

Homey, B., Schelonke, K., Schlegel, C. M., Bruch-Gerharz, D., Weller, K., Kiefer, L., Stölzel, U., Staubach-Renz, P., Wegner, J., Keller-Melchior, R., Walker, G., Bochno, M., & Bilbao, P. (2025). German Cohort Observational Study to Investigate the Short‐ and Long‐Term Safety and Clinical Effectiveness of Afamelanotide 16 mg ( SCENESSE ) in Patients With Erythropoietic Protoporphyria ( EPP ). Photodermatology, Photoimmunology & Photomedicine. https://doi.org/10.1111/phpp.13012

Vancouver

Homey B, Schelonke K, Schlegel CM, Bruch-Gerharz D, Weller K, Kiefer L, et al. German Cohort Observational Study to Investigate the Short‐ and Long‐Term Safety and Clinical Effectiveness of Afamelanotide 16 mg ( SCENESSE ) in Patients With Erythropoietic Protoporphyria ( EPP ). Photodermatology, Photoimmunology & Photomedicine. 2025. doi:10.1111/phpp.13012

BibTeX
@article{Homey2025,
  author = {Homey, Bernhard and Schelonke, Kathrin and Schlegel, Carla Marie and Bruch-Gerharz, Daniela and Weller, Karsten and Kiefer, Lea and Stölzel, Ulrich and Staubach-Renz, Petra and Wegner, Joanna and Keller-Melchior, Regine and Walker, Gillian and Bochno, Malgorzata and Bilbao, Pilar},
  title = {German Cohort Observational Study to Investigate the Short‐ and Long‐Term Safety and Clinical Effectiveness of Afamelanotide 16 mg ( SCENESSE ) in Patients With Erythropoietic Protoporphyria ( EPP )},
  journal = {Photodermatology, Photoimmunology & Photomedicine},
  year = {2025},
  doi = {10.1111/phpp.13012}
}
Start for free →